Phase IIb Protocol 011: Islatravir Plus Doravirine Following Islatravir, Doravirine, Lamivudine Induction in Treatment-Naive Patients Demonstrates Very Low HIV-1 RNA Levels in Patients With Wk 48 Protocol-Defined Virologic Failure

From Dr. Fidelia Bernice and Clinical Care Options (CCO), expert commentary on managing polypharmacy in people with HIV

Fidelia Bernice, PharmD Released: January 6, 2022

Expert faculty discuss guideline recommendations for individualizing ART, from Clinical Care Options (CCO)

Chloe Orkin, MBChB, FRCP, MD
Program Director Jean-Michel Molina, MD, PhD Cristina Mussini, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: December 29, 2021 Expired: December 28, 2022

Overview of Current Patient-Centered ART

Putting Individualized Care into Practice

Future ART: Closing the Remaining Gaps

Dr John Baxter and Clinical Care Options (CCO): Proviral genotyping may help to inform ART choice in patients with suppressed HIV-1 RNA, particularly if preexisting resistance is suspected

John D. Baxter, MD Released: December 29, 2021

From Dr Gregory Huhn and Clinical Care Options (CCO), slides on new data from fall 2021 HIV conferences expand our understanding of adverse events with specific ART regimens